Información del autor
Documentos disponibles escritos por este autor (5)
Añadir el resultado a su cesta Hacer una sugerencia Refinar búsqueda
texto impreso
Wolff, M. ; Shepherd, B.E. ; Cortes, C. ; Rebeiro, P. ; Cesar, C. ; Wagner Cardoso, S. ; Pape, J.W. ; Padgett, D. ; Sierra-Madero, J. ; Echevarria, J. ; McGowan, C.C. ; CCASAnet | Lippincott, Williams & Wilkins | 2019-04-24T18:23:53ZBackground: HIV-infected persons in resource-limited settings may experience high rates of antiretroviral therapy (ART) change, particularly because of toxicity or other nonfailure reasons. Few reports address patient outcomes after these modifi[...]texto impreso
Wolff, Marcelo J. ; Giganti, Mark J. ; Cortes, Claudia P. ; Cahn, Pedro ; Grinsztejn, Beatriz ; Pape, Jean W. ; Padgett, Denis ; Sierra-Madero, Juan ; Gotuzzo, Eduardo ; Duda, Stephany N. ; McGowan, Catherine C. ; Shepherd, Bryan E. ; CCASAnet | Public Library of Science | 2019-01-25T15:02:13ZBACKGROUND: In Latin America, the first wave of HIV-infected patients initiated highly active antiretroviral therapy (HAART) 10 or more years ago. Characterizing their treatment experience and corresponding outcomes across a decade of HAART may [...]texto impreso
Cesar, C. ; Jenkins, C.A. ; Shepherd, B.E. ; Padgett, D. ; Mejia, F. ; Ribeiro, S.R. ; Cortes, C.P. ; Pape, J.W. ; Sierra Madero, J. ; Fink, V. ; Sued, O. ; McGowan, C. ; Cahn, P. ; Grinsztejn, B. ; Reyes, M.W. ; Gotuzzo, E. ; CCASAnet | Elsevier | 2019-04-24T18:23:55ZBackground: Access to combination antiretroviral therapy (ART) is expanding in Latin America (Mexico, Central America, and South America) and the Caribbean. We assessed the incidence of and factors associated with regimen failure and regimen cha[...]texto impreso
Belaunzarán-Zamudio, P.F. ; Caro-Vega, Y.N. ; Shepherd, B.E. ; Crabtree-Ramírez, B.E. ; Luz, P.M. ; Grinsztejn, B. ; Cesar, C. ; Cahn, P. ; Cortes, C. ; Wolff, M. ; Pape, J.W. ; Padgett, D. ; Gotuzzo, E. ; McGowan, C. ; Sierra-Madero, J.G. ; CCASAnet | World Health Organization | 2019-04-24T18:23:51ZObjective To determine the prevalence of adequate monitoring and the costs of measuring CD4+ T-lymphocytes (CD4+ cell) and human immunodeficiency virus (HIV) viral load in people receiving antiretroviral therapy (ART) in seven countries in the W[...]texto impreso
Crabtree-Ramírez, B. ; Caro-Vega, Y. ; Shepherd, B.E. ; Grinsztejn, B. ; Wolff, M. ; Cortes, C.P. ; Padgett, D. ; Carriquiry, G. ; Fink, V. ; Jayathilake, K. ; Person, A.K. ; McGowan, C. ; Sierra-Madero, J. ; CCASAnet | Public Library of Science | 2019-04-24T18:23:56ZBackground: Since 2009, earlier initiation of highly active antiretroviral therapy (HAART) after an opportunistic infection (OI) has been recommended based on lower risks of death and AIDS-related progression found in clinical trials. Delay in H[...]
